Share Name Share Symbol Market Type Share ISIN Share Description
Arix Bioscience Plc LSE:ARIX London Ordinary Share GB00BD045071 ORD 0.001P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 104.50 758 00:00:00
Bid Price Offer Price High Price Low Price Open Price
102.00 107.00 104.50 104.50 104.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.33 42.76 32.10 3.3 142
Last Trade Time Trade Type Trade Size Trade Price Currency
12:35:55 O 758 104.90 GBX

Arix Bioscience (ARIX) Latest News

More Arix Bioscience News
Arix Bioscience Takeover Rumours

Arix Bioscience (ARIX) Discussions and Chat

Arix Bioscience Forums and Chat

Date Time Title Posts
29/11/201916:31Arix Bioscience plc106
30/7/201810:14Arix Bioscience (ARIX) One to Watch -

Add a New Thread

Arix Bioscience (ARIX) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Arix Bioscience trades in real-time

Arix Bioscience (ARIX) Top Chat Posts

DateSubject
08/12/2019
08:20
Arix Bioscience Daily Update: Arix Bioscience Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ARIX. The last closing price for Arix Bioscience was 104.50p.
Arix Bioscience Plc has a 4 week average price of 102p and a 12 week average price of 102p.
The 1 year high share price is 178p while the 1 year low share price is currently 102p.
There are currently 135,551,850 shares in issue and the average daily traded volume is 201,299 shares. The market capitalisation of Arix Bioscience Plc is £141,651,683.25.
23/10/2019
13:38
hashertu: Does ARIX have the means, or authority, to buy back its shares from Woodford/Blackrock? If they believe the company is significantly undervalued at this share price, it might make some sense to do so.
13/9/2019
15:23
tim000: Autolus continues to recover. I estimate NAV currently around £1.73, so the current share price is at a discount of around 30% of NAV.
09/9/2019
08:21
tim000: I've been a buyer today. I agree, they look incredibly cheap. If one strips out their uncommitted cash, the shares are currently trading at a discount of over 40 % to NAV of the portfolio. The true discount is a lot larger, since Autolus (which currently accounts for 17% of total NAV) has been hammered by factors unrelated to its underlying value - namely Woodford, who has now sold much of his holding. You've probably noticed that Autolus has risen about 40% in the past two days, I expect that to continue as it's currently trading at a 40% discount to its latest capital raise. Were the Autolus share price to return to that level, ARIX's NAV would increase by 20p per share. Finally, over half of ARIX's portfolio is located in the US and is valued in $. So future sterling weakness against the $ (which seems likely) will further increase ARIX's NAV.
08/6/2019
19:38
rambutan2: Yes x2 ie WIM’s large direct stake in ARIX, and also the plummet in AUTL’s share price due to WIM’s large stake in that, which is of course ARIX’s largest holding. And on top of that, who read the AGM voting rns? The greedy management are hopefully going to start pruning their pay! https://uk.advfn.com/stock-market/london/arix-bioscience-ARIX/share-news/Arix-Bioscience-plc-Correction-Result-of-AGM/80056948
31/3/2019
19:25
rambutan2: Agree. Only gripe is the still too high costs. Hasn't really shifted the share price, I assume due to Woodford overhang worries, but confirms that currently on offer at a 25% discount to nav. Worth noting that at 31/12, AUTL which is easily the largest investment, closed at $32. At close on fri it was around that price, so ARIX's nav is a still valid one. Also even after post y/e fundings, by my calcs there is still well over £70m of cash on the balance sheet. LONDON, 28 March, 2019: Arix Bioscience plc (LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences, today announces its annual results for the year ended 31 December 2018. Financial highlights * GBP70m net positive revaluation of the portfolio[1] * GBP52m invested across the portfolio and a further GBP16m post year-end[2] * Gross portfolio value increased to GBP175m (2017: GBP54m) * Net Asset Value increased to GBP270m (2017: GBP146m) * GBP87m capital raise in March 2018 * NAV per share increased to GBP2.00 (2017: GBP1.52) Operational highlights * Nasdaq listing of four Arix companies[3] * Positive portfolio progression; 26 clinical trials underway; 19 expected readouts in 2019[4] * $555m capital raised by Arix portfolio companies in 2018 * New commercial partnerships added with Fosun, Ipsen and Fred Hutchinson Cancer Research Center Post period end investments: * Co-led $63m Series B for Imara, a clinical stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies; committing $15m (GBP11.3m) * Harpoon completed a successful IPO on Nasdaq, raising $81m; Arix invested $6m (GBP4.6m) to retain a stake of 12.1% Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented: "We are encouraged by progress in 2018 with a number of positive developments in our business, and a net increase of GBP70m in the value of our portfolio companies. Overall, we grew our Net Asset Value from GBP146m at the beginning of 2018 to GBP270m at year end which, on a per share basis, was an increase of 32% over the year. "This performance is an early sign, I believe, of the potential in our business and the strength of the young portfolio we have built. We are well positioned for further growth and investment in 2019 and look forward to the year ahead with confidence and optimism". https://uk.advfn.com/stock-market/london/arix-bioscience-ARIX/share-news/Arix-Bioscience-plc-Annual-Results-for-the-year-en/79567281
20/10/2018
08:43
skyship: The LogicBio flotation results in a mark-up in the ARIX stated NAV to 200p; and with the LOGC share price moving ahead from the listing price of $10.00 to close at $11.50, the NAV now at 204.5p. Of course, it is stated/assumed that there is much hidden value within the ARIX portfolio, so any further evidence of such may now instigate a move back up to the 200p level... Incidentally, a look at two of their other US-listed holdings shows Autolus (our largest holding) has added c£10m since 30th June; whilst Iterum has lost c£3.5m over the same period.
17/8/2018
12:16
pdt: Does today's news of a 3m share sale explain the recent decline in the share price? On a separate note I saw a positive article on the work being undertaken by Artios in today's Daily Mail; hTTp://www.dailymail.co.uk/news/article-6068949/New-cancer-pill-stops-tumor-cells-repairing-making-sensitive-radiotherapy.html
15/5/2018
10:10
eaaxs06: Encouraging to see more buy trades going through' than sells' over the past week and a half or so. Let's hope this is the start of more interest in the shares and a strengthening share price.
03/1/2018
14:06
eaaxs06: Good to see the share price perking up this year, let's hope it contines.
Arix Bioscience share price data is direct from the London Stock Exchange
Your Recent History
LSE
ARIX
Arix Biosc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191208 11:22:49